CVS
Strong BuySecond WindFLAGCVS Health Corporation · Healthcare · United States · $119.0B · Avg Vol: $624M/d
Second Wind: Cheap and rising again, but the business does not yet earn the optimism.
CVS Health has exceptional momentum at M87, the strongest in this batch, but quality at Q46 is below the calibrated floor, so stage one fails. Insider selling of 0.26% is separately adverse.
The ranks quoted here are from the day it was written; today's Quality, Value and Momentum are the bars above.
ABOUT CVS HEALTH CORPORATION
Read
CVS Health Corporation is an integrated healthcare company operating retail pharmacies (CVS Pharmacy), pharmacy benefit management services (CVS Caremark), and health insurance plans (Aetna). Its competitive moat is built on unmatched scale and vertical integration across pharmacy, PBM, and insurance segments, creating a comprehensive healthcare ecosystem. CVS Health is one of the largest integrated healthcare providers in the U.S., offering a broad range of health services.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 322.5B | 357.8B | 372.8B | 402.1B | 7.6% | 412.6B | 417.7B | 429.5B | 3.4% |
| EPS | 3.29 | 6.49 | 3.67 | 1.40 | -24.8% | 3.79 | 1.66 | 1.77 | 12.4% |
| Shares | 1.3B | 1.3B | 1.3B | 1.3B | -2.2% | 1.3B | — | — | — |
| Debt | 70.7B | 79.4B | 82.9B | 80.0B | 4.2% | 76.3B | — | — | — |
| Equity | 71.5B | 76.5B | 75.6B | 75.2B | 1.7% | — | — | — | — |
| Op CF | 16.2B | 13.4B | 9.1B | 10.6B | -13.0% | 14.8B | — | — | — |
| Inv CF | -5.0B | -20.9B | -7.6B | -5.9B | — | — | — | — | — |
| Fin CF | -10.5B | 2.7B | -1.1B | -4.9B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CVS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CVS | CVS Health Corporation(you) | $119.0B | 93 | Strong Buy |
| ELV | Elevance Health, Inc. | $85.5B | 90 | Strong Buy |
| CI | The Cigna Group | $73.7B | 92 | Strong Buy |
| HUM | Humana Inc. | $46.3B | 89 | Strong Buy |
| UNH | UnitedHealth Group Incorporated | $352.7B | 90 | Strong Buy |
| CNC | Centene Corporation | $32.0B | 93 | Strong Buy |
| OSCR | Oscar Health, Inc. | $9.4B | 98 | Strong Buy |
| SAUD3.SA | Bradsaúde S.A. | $7.9B | 98 | Strong Buy |
| MOH | Molina Healthcare, Inc. | $10.4B | 71 | Buy |
| PGNY | Progyny, Inc. | $2.0B | 98 | Strong Buy |
Peer medians: ROE 2.7% · P/E 23.6x · Gross margin 52.5%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.